Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240267 | 1.00 | ALDH1A1 (0.42) | ALDH1A1LMNAGPR52GRIN2CMRGPRX4 | |
| SCHEMBL9102502 | 0.92 | SCD (0.43) | ALDH1A1LMNAGPR52GRIN2CMRGPRX4 | |
| SCHEMBL9102506 | 0.92 | SCD (0.43) | ALDH1A1LMNAGPR52GRIN2CMRGPRX4 | |
| SCHEMBL1241275 | 0.88 | CCR2 (0.42) | ALDH1A1LMNAGRIN2CMRGPRX4KMT2A | |
| SCHEMBL1241273 | 0.88 | CCR2 (0.42) | ALDH1A1LMNAGRIN2CMRGPRX4KMT2A | |
| SCHEMBL1241568 | 0.88 | HRH3 (0.46) | LMNAMRGPRX4VNN1TRPV1HRH3 | |
| SCHEMBL1241570 | 0.88 | HRH3 (0.46) | LMNAMRGPRX4VNN1TRPV1HRH3 | |
| SCHEMBL9100118 | 0.87 | BRAF (0.45) | LMNAPOLBHTR2A | |
| SCHEMBL9100122 | 0.87 | BRAF (0.45) | LMNAPOLBHTR2A | |
| SCHEMBL1241560 | 0.87 | SORT1 (0.43) | ALDH1A1LMNAKMT2AVNN1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | claimed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | claimed |
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | ALDH1A1 3784/4885LMNA 1079/4885GPR52 2295/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | ALDH1A1 3784/4885LMNA 1079/4885GPR52 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.